Shockwave therapy, or Extracorporeal shockwave therapy (ESWT) to give it its full nomenclature, sends mechanical shock waves into the affected area to stimulate the natural healing process by triggering the body’s own repair mechanisms.
The therapy is being spearheaded at Willows by Kinley Smith (pictured right), an RCVS and European specialist in small animal surgery. He said: "Shockwave therapy is a whole new line of treatment and has proved a spectacular success.
"It’s an excellent technique for dealing with certain orthopaedic conditions and there’s no invasive surgery, no wound to heal and no risk of infection so it really is a win-win-win procedure.
"It is particularly effective in the treatment of ligament and tendon injuries.
"There can be immediate pain relief for the dog; after two weeks we start to see lasting benefits and in four weeks we normally see a clear improvement.
"The added bonuses are we can normally reduce any medication; the dog can enjoy more exercise plus it is not as costly as undergoing an operation.
"Surgery is still essential in some of the more acute, problematic cases but shockwave therapy has been a terrific development in helping us provide an alternative treatment in a lot of soft tissue, muscle and bone conditions."
For more information, visit www.willows.uk.net.
The support pack features information on the role anaesthetic induction agents can play in the maintenance of anaesthesia to help veterinary surgeons provide appropriate care for their patients.
The pack includes a user guide to achieving the best outcome when using Alfaxan for the induction and maintenance of anaesthesia, a summary of peer-reviewed key clinical papers on the use of Alfaxan and how it can be used for the maintenance of anaesthesia, an article discussing the use of intravenous agents to maintain anaesthesia in the dog and cat, frequently asked questions and an Alfaxan dosage chart for CRI (Constant Rate Infusion) and intermittent bolus.
To download the pack, visit www.alfaxan.co.uk.
Richard Beckwith, country manager for Jurox (UK) Ltd. said: "We have received a significant increase in enquiries following the isoflurane supply issues.
"The new support pack will provide veterinary professionals with comprehensive information on Alfaxan to help practices develop options in providing appropriate anaesthesia for patients."
For more information, call Jurox customer services on 0800 500 3171, or e-mail: info@jurox.co.uk.
1,219 farmers took part in the survey: 44% beef and 56% dairy. For the first time, the survey was also tailored for the regions. 488 responses came from famers in England, 380 from Scotland, 164 from Wales and 237 from Northern Ireland.
Boehringer Ingelheim’s Matt Yarnall, who led the project, said: "Headline findings are that farmers have regrets about holding onto persistently infected animals (PIs) which, at the end of the day, no-one should be doing.
"The financial benefit of being free of BVD was estimated as being over £90 per cow per year and when asked what impact BVD has had on their herd, the majority of producers highlighted poor fertility and high levels of disease in the herd.”
Boehringer says the identification of persistently infected animals (PIs) through tag and testing, supported by improved herd biosecurity and vaccination, could cost as little as £10 per cow per year, representing a significant return on investment for a disease with severe financial impact.
Matt said: "Herd biosecurity is also hugely variable. The most commonly selected response was operating a closed herd but, as most practitioners will know, the definition of a true closed herd and the real-life execution of that can be two very different things."
Highlighting one of the other major challenges for producers in cattle-dense areas, results from Scotland that showed that 51% of farmers with neighbouring cattle are worried about their neighbours' BVD status.
Matt said: "Perhaps the most alarming finding was the lack of awareness of the intricacies of some BVD vaccination courses, especially around when they need to be restarted, in order to achieve the protection needed."
2017 survey data from last year showed that 71% of producers were failing to achieve adequate protection when using a BVD vaccine that requires a booster six months after the primary course.
Boehringer says the results showed this is mostly down to not properly understanding the exact nature of the timings for the two-dose primary course, dates of service and calving and then the booster date.
Matt added: "For any practitioner advising clients, the 2018 finding that a shocking 85% haven’t restarted a vaccination course when the majority should have done, should ideally serve as a clear call to action."
For more information about the findings of the National BVD Survey, email bvdzero.uk@boehringer-ingelheim.com.
The charge against Dr Irvine was that in July 2017, he failed to discuss with the owners alternative treatment options to dental surgery under general anaesthetic, or the risks of dental surgery under general anaesthetic, and failed to obtain informed consent from the owners for the surgery.
Dr Vasilev was also originally charged with failing to discuss alternative treatment options or the risks of the surgery and failing to obtain informed consent. However, at the outset of the hearing, as a result of new information which came to light, the RCVS opted to offer no evidence in relation to these charges. Mr Vasilev was separately charged with failing to maintain clear, accurate and detailed clinical records in relation to his treatment of the dog.
At the outset of the hearing, Mr Irvine denied all aspects of the charge against him; while Dr Vasilev admitted all aspects of the remaining charge.
The Committee heard how Rupert's dental surgery under general anaesthetic was recommended by Mr Irvine on 10th July and performed by Dr Vasilev on 11th July 2017. After the surgery, Rupert was discharged, but vomited in his sleep that same night. He was brought back to the practice on 12th July, where Dr Vasilev administered antiemetic and antibiotic medication.
However, Rupert continued to vomit over the next five days, and was seen by the practice on 17th July and then on 18th when blood tests were conducted. Rupert’s condition deteriorated as he continued to vomit and lose weight and he was brought back to the practice on 22nd July where he was euthanased by Dr Vasilev.
The Committee heard evidence from Rupert’s owners as well as two expert witnesses. It found the first aspect of the charge against Mr Irvine proven on the basis that there was an inadequate discussion with the owners regarding the option of delaying the dental treatment on Rupert because of his recent ascites caused by congestive heart failure.
The Committee found the second aspect of the charge against Mr Irvine proven on the basis that he had not discussed the risks of Rupert undergoing general anaesthetic given the recent diagnosis of congestive heart failure, following which (in relation to the third aspect of the charge against Mr Irvine), it was therefore found proven that he had failed to gain informed consent.
With all aspects of the charge against Mr Irvine being proven, and with Dr Vasilev admitting the charge against him, the Committee went on to consider if the proven and admitted charges against both amounted to serious professional misconduct.
In respect of Mr Irvine, Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The Committee was not persuaded that the failure to obtain informed consent from [the owner] and discuss matters further with her on 10th July 2017 in the circumstances of this case would amount to serious professional misconduct which would bring the profession into disrepute.
"In the Committee’s judgment, the breach of standards, whilst amounting to professional misconduct, was not serious professional misconduct, in the context of other discussions which had taken place…. The Committee further decided that a finding of serious professional misconduct in this case would be disproportionate having taken into consideration the discussions that Mr Irvine had with [the owner] prior to 10th July 2017 and the fact he was dealing with a complex and changing case.
"The Committee therefore found that Mr Irvine was not guilty of disgraceful conduct in a professional respect."
The Committee noted that Dr Vasilev had admitted breaching the Code of Professional Conduct for Veterinary Surgeons in respect of failing to keep adequate clinical and client records.
However, in mitigation, the Committee considered a number of factors including that, in failing to maintain adequate notes related to Rupert’s treatment, Dr Vasilev had followed the standard of notetaking in the practice as set out by Mr Irvine who was practice principal; that Dr Vasilev had only worked with Mr Irvine in the UK and his record-keeping was limited to working in one practice; that Dr Vasilev admitted his failures at an early stage of the proceedings; that he had made efforts to avoid repetition in the future by undertaking webinars and research; and, that he had shown insight into the need to ensure full communication and detailed note-taking.
Stuart Drummond added: "In relation to Dr Vasilev, the Committee was satisfied that [his] standard of record-keeping was in breach of the Code of Professional Conduct for Veterinary Surgeons and that the breach… amounted to professional misconduct.
"The Committee concluded that the breaches overall, when considering the context and number of mitigating factors, were, in the Committee’s view, insufficient to amount to serious professional misconduct…. Accordingly it found Dr Vasilev not guilty of disgraceful conduct in a professional respect."
The full facts and findings from the case can be found at www.rcvs.org.uk/disciplinary.
Fitzpatrick Referrals has announced the launch of a new cancer and soft tissue surgery referral service headed by Professor Nick Bacon (pictured right) and Dr Laurent Findji.
Professor Bacon and Dr Findji are American and European Board-Certified Surgeons respectively, with extensive experience in cancer care and soft tissue surgery innovation.
Professor Bacon joins the service directly from his post as Head of Oncology at the University of Florida, College of Veterinary Medicine. He will also take up the position of part-time Chair of Oncology at the new University of Surrey School of Veterinary Medicine.
Dr Findji joins the team from his prior role as director of the VRCC in Essex, bringing his expertise in cancer and soft tissue surgery advancements.
Professor Noel Fitzpatrick, founder of Fitzpatrick Referrals, said: "With these two eminent and globally recognised Specialists leading the new service, the UK will now be able to provide an innovative approach and comprehensive diagnosis, treatment, management and prognosis for all cancer and soft-tissue patients. The service will also be able to use the additional expertise available through the University of Surrey and both Specialists will be available for referring vets to discuss cases and to offer advice on the innovative treatment options available."
Professor Stuart Carmichael, the new service's director, said: "We would only introduce a service like this when we know it can provide the best options, the most comprehensive care and the highest level of expertise available. This is a referral service which will change the way that cancer patients are dealt with in the UK."
Noel added: "It's a testament to the reputation of Fitzpatrick Referrals and the University of Surrey, our partner in education, that we have been able to attract talents as great as Nick and Laurent. This is an exciting time not only for the hospital, but also for first-opinion practices throughout the UK who can avail of this world-class opportunity to offer a potentially life-saving service to their clients for their patients."
The service will operate initially from a self-contained clinic at the existing Fitzpatrick Referrals Orthopaedic + Neurology Hospital in Surrey and will be accepting patients from 1st October.
The patient was a four-year-old Labrador called Vinny who, in 2019, became the first dog in the UK to receive a BioMedtrix canine ankle replacement system, implanted by Wear's Head of Orthopaedic Surgery, RCVS Specialist Neil Burton, assisted by Maciej Krukowski.
That first surgery, on Vinny’s right ankle, was successful. However, two years later he needed similar treatment to his left leg.
Neil said: “Vinny first presented to us at Wear Referrals in 2019 with hind limb lameness.
“He was diagnosed with osteoarthritis in his hock joints bilaterally due to a developmental condition called osteochondrosis of the talus causing him ongoing pain and lameness. We operated on the right ankle, with Vinny becoming the first dog in the UK to have this ankle replacement system placed.
“Vinny was significantly more comfortable on this limb postoperatively but his lameness progressively worsened in the left hind limb. The decision was made to perform the same surgery on the left ankle, making Vinny the first dog in the world to have this surgery performed bilaterally.
“Vinny has made another fine recovery from surgery and is now off medication, meaning he can exercise unrestricted and pain-free without a lifetime reliance on painkilling drugs.
“For our team at Wear to be able to offer him this pioneering surgery has been a great opportunity. He’s now a unique case, being both the first UK recipient of this BioMedtrix joint replacement as well as the world's first bilateral ankle replacement with the same system.”
For more information, visit www.wear-referrals.co.uk.
The RCVS has opened a consultation on the future of veterinary specialisation, which includes a proposal that the use of postnominals and titles by veterinary surgeons should be rationalised in order to avoid confusion amongst the public.
The proposals are submitted for comment by the RCVS Specialisation Working Party, which is chaired by former Chief Medical Officer Professor Sir Kenneth Calman.
The Working Party's review was precipitated by a finding that the structure of veterinary specialisation is "confusing and opaque" to both animal owners and the profession (Unlocking Potential - a Report on Veterinary Expertise in Food Animal Production, by Professor Philip Lowe, 2009).
The Working Party has explored the routes to RCVS Recognised Specialist status. It has also looked at the use of 'specialist' more broadly, given the fact that it is not a protected term in the veterinary field, and has considered animal owners' expectations of a 'specialist'.
The Working Party also makes proposals for encouraging more veterinary surgeons to become specialists, given that there are currently only 319 on the RCVS List of Recognised Specialists, out of a UK practising arm of the profession of some 17,400 veterinary surgeons.
The proposals from the Working Party could have far-reaching impact. One suggestion is that all those meeting the criteria for specialist status would also become Fellows of the RCVS (FRCVS) - a status currently only held by those who complete a thesis or exam, or who qualify on the basis of 'meritorious contributions to learning'. There are also proposals that the term 'RCVS Recognised Specialist' be dropped and replaced with the much simpler term 'specialist' or 'veterinary specialist'.
Further proposals include the introduction of a 'middle tier' of veterinary surgeons - potentially to be called 'advanced practitioners' - who would be below full specialist status and subject to periodic revalidation.
There are also recommendations that veterinary surgeons should be obliged to explain referral options to their clients, including the level of expertise of those to whom they are referring cases.
The future of the RCVS subject boards, which currently manage the various Certificate and Diploma examinations, is also considered in the proposals.
The emphasis throughout is on simplification and improvement, according to Professor Sir Kenneth Calman, who said: "New legislation to introduce statutory registration for veterinary specialists would no doubt make things clearer, as it is for doctors and dentists, but, in the meantime, we believe there are a number of actions which the RCVS could take to improve matters."
The consultation paper can be downloaded from www.rcvs.org.uk/consultations, and comments are welcomed from members of the public, veterinary surgeons and veterinary nurses. The closing deadline for comments, which should be sent to RCVS Head of Education, Freda Andrews, on f.andrews@rcvs.org.uk, is Friday 9 December.
Comments received will be considered by the RCVS committees and Council in early 2012.
The technology, developed by US firm SignalPET, sends X-rays through an AI machine algorithm to get a more or less instantaneous report, rather than needing a radiology specialist to analyse results, which can take up to three days.
IVC starting trialling the system with 22 of its practices last November and it quickly became clear that there were huge benefits, including saving time for clinicians, cost, and improving confidence in the diagnosis.
The majority of IVC's trial teams said they viewed the technology as a positive diagnostic aid, supporting their own professional opinion.
It also served as a learning tool, increasing the confidence and clinical independence of younger or newly qualified vets.
Sarah Merrell, Clinical Director at Lincvet, a group of IVC Evidensia practices in Lincoln and one of the trial clinics, said: “SignalPET has proved really valuable – giving us excellent support for radiography.
"It has been used by both our highly experienced and newly graduated clinicians to get a second set of ‘eyes’ on our cases giving reassurance and support when reading our radiographs.
“Overall, it has improved clinician confidence, reduced the pressure on senior vets, given us an additional tool for training and development, and greatly enhanced client understanding of our findings.”
Alistair Cliff, IVC Evidensia’s Deputy Chief Medical Officer, said: “The AI radiology process developed by SignalPET represents a real revolution in how results are analysed.
"The overwhelming success of our initial trial in November means we are confident in pushing ahead with rolling out the technology in the UK this year and eventually, in Europe too."
Dechra Veterinary Products has announced that it will be launching Zycortal, a new medication for the treatment of canine hypoadrenocorticism at the BSAVA Congress in April.
Zycortal is a prolonged-release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with Addison’s disease. Dechra says it has proved highly effective in clinical trials with more than 80% of dogs responding positively to treatment1.
Zycortal contains desoxycortone pivalate (DOCP) which Dechra says controls serum electrolytes more effectively than fludrocortisone2 (the human treatment currently prescribed for dogs with Addison’s disease) and is considered the preferential drug for mineralocorticoid supplementation.
Zycortal is the only European licensed treatment for canine hypoadrenocorticism and adds to Dechra’s existing endocrinology range.
Visitors to the BSAVA Congress will be able to find out more about Zycortal at the Dechra stand (500). Delegates are also invited to attend a presentation by Professor Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS on Saturday, April 9, at 11.10am.
The presentation, New developments in the diagnosis and management of Addison’s disease aims to give delegates an insight into the condition.
Dechra Brand Manager Craig Sankey said: "We are very excited to be able to bring Zycortal to veterinary professionals in the UK. Addison’s disease can be very hard to diagnose as it mimics so many other illnesses.
"Each injection of Zycortal lasts approximately one month, providing long-term control of primary Addison’s disease. The prognosis for dogs with Addison’s disease is excellent provided that treatment is maintained for life. Our team will be on hand at the BSAVA Congress to explain and discuss the benefits that Zycortal can bring to their day to day practice in the fight against this illness."
References
The survey, which this year had a record 1605 respondents, covers everything from basic earnings, bonuses and dividends to benefits such as accommodation, car allowance and pensions.
The survey found that the median salary package for all vets in 2021 was £48,325; £3000 more than in 2020.
For all nurses the median package was £24,227 in 2021 and for head nurses the figure rose to £31,013.
The median daily rate for a locum vet was £350 in 2021, a rise of over 16% since 2020.
The hourly locum rate increased by 36% to £41 per hour.
Similarly, locum nurse daily rates have risen by over 30% since 2020 to £144 and their hourly rate increased by 14% to £20.
New grad vets' salary packages actually dropped by £800 in 2021, to £32,700.
However, the 2021 new grad hourly rate increased to £15.66 from £15.04 in 2020.
SPVS says this could indicate that newly qualified vets are earning less because they are working, on average, three hours less a week.
This may suggest that they are prioritising their work life balance, with time off being more important than an overall salary.
SPVS also highlights a growing gender gap in salary.
81% of the respondents were female, and the median full time salary difference between men and women was 21%, compared to 15% in 2020.
SPVS hypothesises that this could be because there are more male vets in more senior positions, rather than because of gender per se.
The question, therefore, is why there are more male vets than females in senior positions.
The survey showed very similar numbers of males and females doing both clinical and non-clinical post graduate training. But more than twice as many men than women go on to take up positions of leadership or seniority, or in referrals.
More research is needed to understand why females are doing the extra training, but apparently not using it to further their career.
As in 2020 SPVS has also looked at satisfaction with remuneration, hours worked, conditions, support and prospects and is using this data to create a separate report which will be available soon.
For more information, visit: https://spvs.org.uk/spvs-survey/
Rominervin contains 10 mg/ml romifidine hydrochloride, equivalent to 8.76 mg romifidine, presented in a 20 ml vial.
It can be used as a sedative to facilitate handling, examination, minor surgical interventions and minor procedures or as a premedication prior to administration of injectable or inhalation anaesthetics.
Rominervin can also be used in combination with synthetic opiates such as butorphanol to provide deeper sedation or analgesia.
Dechra Brand Manager Emma Jennings said: "Rominervin is highly effective as it has a longer duration of action than other alpha-2 agonists1. It starts to work within one to two minutes with maximum sedation achieved between five and 10 minutes.
"It is yet another valuable addition in our equine anaesthesia and analgesia range that has been designed to provide vets with the therapies they need to operate successfully in day-to-day practice."
Rominervin can be used in conjunction with Dechra’s equine anaesthesia and analgesia app, designed to help veterinary professionals choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates.
For more information visit: www.dechra.co.uk/products/equine
Michael qualified from the University of Glasgow in 2009 and then worked in first opinion practice in Buckinghamshire and Northern Ireland. He then returned to the University of Glasgow in 2012 to further his training and experience in oncology by completing four years of additional training. He completed an ECVIM residency in oncology in 2016 and became a Diplomate of the European College of Veterinary Internal Medicine and a European Specialist in Oncology in 2017. Michael worked at a private referral practice in Surrey prior to joining Fitzpatrick Referrals. Earlier this year, Michael was awarded a Masters degree in Veterinary Medicine. This additional qualification researched canine mast cell tumours.
Michael said: "I am absolutely delighted to have joined Fitzpatrick Referrals Oncology and Soft Tissue hospital. I have had a long-standing ambition to work as part of the fantastic team here since visiting the hospital during my specialist training in 2015. At this visit, I immediately felt at home in a group of people driven to deliver the very best compassionate care for dogs and cats.
"My ambition is to develop the very best ways to minimise the impact that cancer has on animals. I know that Fitzpatrick Referrals is the best environment for me to be able to achieve this. Throughout the hospital, there is an amazing positive attitude and a collective drive to improve the overall care we can give to pets with cancer. I am also excited by the opportunity to be able to help others to achieve their goals in improving cancer care for pets."
Vetoquinol has announced the introduction of Melovem to the UK market. Melovem is a new injectable preparation containing 5mg/ml meloxicam which is licensed for use in pigs and young cattle.
According to the company, meloxicam is the most widely used veterinary non steroidal anti-inflammatory injection in the UK. Presented in 100ml bottles, with a lower dose formulation, Melovem can be a cost-effective NSAID solution to leave on-farm.
Mark Leddy from Vetoquinol said: "We are pleased to be the distributors of Melovem in the UK. Melovem provides vets and farmers with a new, cost-effective meloxicam injection that is suitable for on-farm use."
Contact your Vetoquinol representative for more information on Melovem, or call Vetoquinol on 0800 1608197.
The company says Taurador Pour-on provides a stress-free, easy to use treatment, with persistent activity against a large number of cattle parasites, therefore ensuring effective coverage over long periods of the grazing season.
Matthew Swanborough BVSc MRCVS, Veterinary Advisor for Norbrook, said: "The farming industry will be aware that heavy worm burdens can significantly affect the health and productivity of cattle, potentially as much as £100 per head of cattle. We cannot simply ignore these parasites but we must tackle them responsibly. A comprehensive worming strategy is a vital component of any animal health plan, which should be composed of management strategies and any necessary anthelmintic treatments."
Norbrook highlights the product's efficacy against the gutworms Osterstagia osterstagi, Cooperia oncophora and lungworm, Dictyocaulus viviparous, with persistent action against these parasites for 35 days, 28 days and 42 days respectively.
Doramectin, the active ingredient in Taurador, is an anthelmintic belonging to the macrocyclic lactones (3-ML) group, along with ivermectins. Norbrook says both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods.
Dr Leigh Sullivan, Norbrook Large Animal Product Manager, said: "Taurador is the company’s thirteenth new product introduction in the last four years and it is a significant addition to our portfolio. Internal parasites such as gutworms and lungworm can have a serious impact on animal health and welfare, as well as financial implications for farmers, so it is great to be able to provide another product to help reduce the economic impact of these parasites."
Taurador is available in three different pack sizes (1L; 2.5L and 5L) and an appropriate dosing applicator is also available.
Neptra has been approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.
Mario Andreoli, Head of Marketing at Bayer Animal Health, said: "Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian.
"Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice."
No at-home applications by the dog owner are required. The treatment stays in the hands of the vet who has full control over compliance.
Mario added: "With Neptra we provide a high-quality veterinary treatment that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application."
VetSurgeon understands the new product will be available in the UK in January 2020.
Founded by Peter Rossdale in Newmarket in 1959, the practice now boasts a team of 50 veterinary surgeons and has established an international reputation for providing world class ambulatory, referral and laboratory services. The team is led by RCVS, European and American recognised veterinary specialists and operates from four sites in Newmarket, Exning, Hertfordshire and Lambourn.
Each year, Rossdales Equine Hospital in Exning hosts a large number of CPD courses which often include internationally recognised guest speakers who lecture alongside Rossdales’ specialist clinicians, with delegates attending from as far afield as Europe, Singapore, Dubai and Australia.
To celebrate the practice’s Diamond anniversary, Rossdales is hosting a special 'Diamond Series' of CPD events in 2019 in addition to its usual programme of educational courses.
Mike Shepherd, Managing Partner at Rossdales, said: "Since the practice was established by Peter Rossdale in 1959, it has always prided itself on clinical research and the willing distribution of this and other information to the veterinary profession. This ‘Diamond Anniversary’ series of CPD events is an initiative that we hope will benefit many of our veterinary colleagues. The first of these special events, the Diamond Series Veterinary Nursing Congress, was held at the beginning of June and was fully subscribed. We’re very pleased by the excellent feedback it generated."
Two further ‘Diamond Series’ events are scheduled, for veterinary surgeons and veterinary students respectively:
The Diamond Series Veterinary Surgeons Congress takes place on Friday,12th and Saturday, 13th July 2019 and is for all veterinary surgeons with an interest in equine or mixed practice. The programme covers a wide area of subjects, with talks provided by 12 veterinary surgeons from Rossdales Equine Hospital and Rossdales Laboratories. It also includes admission to The Moët & Chandon July Festival at Newmarket Racecourse on Saturday, 13th July.
The Diamond Series Undergraduate Congress will take place on Saturday, 10th and Sunday, 11th August 2019. This course is aimed at all current veterinary undergraduates who want to gain more knowledge and experience in the fields of equine veterinary medicine and surgery. There will be talks and presentations from 9 veterinary surgeons from Rossdales Equine Practice, Rossdales Equine Hospital and Rossdales Laboratories. There will also be a course dinner on the Saturday evening.
For more information, visit www.rossdales.com/news-events.
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
For the study, which was funded by the charity Songbird Survival, researchers collected the nests of 103 blue and great tits, and tested them for the presence of 20 insecticides.
Fipronil, imidacloprid and permethrin were the main culprits, detected in 100%, 89.1% and 89.1% of the samples respectively.
Overall, a higher number of either dead offspring or unhatched eggs was found in nests containing a higher number of insecticides, higher total concentration of insecticides or a higher concentration of fipronil, imidacloprid or permethrin, which the authors say suggests contact exposure of eggs to insecticides in nest lining may lead to mortality and lower reproductive success.
The BVA responded by calling for more research and encouraging vets to work with clients to ensure responsible use of parasiticides.
BVA President Elizabeth Mullineaux said: “Parasiticides play an important role in preventing and treating parasites in animals, which if left unaddressed can lead to bigger health and welfare issues in both animals and people.
"But it’s important they are used responsibly, and this work from the University of Sussex and SongBird Survival highlights the need for more research into how parasiticides affect the environment and wildlife and the associated risks.
“Rather than blanket use, we strongly encourage vets and owners to take a risk-based approach to prescribing or recommending these medicines, reflecting an animal’s exposure to parasites."
Reference
Hill's Pet Nutrition is to launch Prescription Diet y/d Feline for the nutritional management of feline hyperthyroidism in May.
According to the company, hyperthyroidism is the most commonly diagnosed endocrinopathy in cats globally, and is thought to affect around 10% of cats over the age of nine in the UK.1.
Prescription Diet y/d Feline is clinically proven to manage thyroid health in three weeks3 and gives vets a new management modality to address the needs of hyperthyroid cats. Hill's says that the new product is essentially a low iodine food; production of thyroid hormones T3 and T4 require iodine molecules, so limiting the amount of dietary iodine reduces the amount of thyroid hormones produced and released by the thyroid gland.
Hill's highlights three key studies in peer reviewed veterinary journals which the company says demonstrates the efficacy of y/d.2-4 The research identified that limiting the amount of iodine consumed resulted in a lowering of T4 (serum total thyroxine) to normal levels, with significant reductions in just 3 weeks.2
Hill's says that the availabillity of nutrition as a treatment option marks a major step forward from invasive surgery, treatment with radioactive iodine - which is available in only a few centres in the UK - or pilling, which can prove to be particularly difficult for some pet owners. The company adds that a gradual transition to y/d is also an option where medical treatment is proving problematic.
Cats with hyperthyroidism have a multisystemic disease and concurrent problems can develop, such as hypertension, cardiovascular abnormalities and recurrent urinary infections. Additionally, many older cats with hyperthyroidism have concurrent renal dysfunction, which is often 'unmasked' when the hypertension is bought under control. Therefore, y/d also has controlled levels of phosphorus and low sodium for renal and circulatory health, reduced magnesium and moderate urine pH target for urinary health and taurine and carnitine for heart health.
Hill's Prescription Diet y/d Feline will be available from 1st May.
For more information, visit www.catthyroidhealth.com
1. Symes H, Winter 2008/2009. Feline hyperthyroidism. The Endocrinologist. Issue 90, pp 10-12. Symes H, Winter 2008/2009. Feline hyperthyroidism. The Endocrinologist. Issue 90, pp 10-12.2. Controlled level of dietary iodine normalizes serum total thyroxine in cats with naturally occurring hyperthyroidism Yu S, Wedekind KJ, Burris PA, et al. J Vet Intern Med 2011;25:683-684 (abstract).3. Titration of dietary iodine for reducing serum thyroxine concentrations in newly diagnosed hyperthyroid cats Melendez LD, Yamka RM, Forrester SD, et al. J Vet Intern Med 2011;25:683 (abstract).4. Titration of dietary iodine for maintaining normal serum thyroxine concentrations in hyperthyroid cats Melendez LD, Yamka RM, Burris PA. J Vet Intern Med 2011;25:683 (abstract).
In 2020, BSAVA Congress will have been held at the ICC Birmingham for thirty years. However, recent years have seen ever greater competition from the London Vet Show, so the plan to revitalise the event further north at an award-winning new venue with such good transport links seems to make a lot of sense.
Manchester Central's size also means that unlike in Birmingham, the commercial exhibition, lectures and demonstrations will all take place under one roof, maximising the use of delegates' time.
Angharad Belcher, Head of BSAVA Congress said: "We’ve had a first-class experience in Birmingham, and we could not have asked for more from the venue. We know that 2019 and 2020 will continue to be popular, however, it’s time to move BSAVA Congress forward and revitalise the offering to our delegates and exhibitors by bringing everything into one building. The move to Manchester enables us to invest even more in speakers and delegate experiences, to make BSAVA’s education programme truly unsurpassable."
BSAVA President Philip Lhermette said: "It’s very much a new city for a new Congress and celebrations will be in order. Manchester lends itself perfectly to a timely transformation for Congress. We will be completely re-branding the event, modernising the CPD programme and making the best possible use of every minute of every delegate’s time over the full four days. We have been working closely with the city and venue in practical terms to offer a whole suite of options to delegates and exhibitors, from irresistible new socials and extensive accommodation choices, to easy transport routes."
Shaun Hinds, CEO of Manchester Central said: "After getting to know the association and their vision, it was clear that they wanted to transform the experience of their delegates. The ambition of the association matches that of the city and Manchester has the perfect blend of venue and vibrancy to develop the BSAVA Congress of the future. We’re delighted to be welcoming them in 2021 and we’ll work hard with the organisers to create a unique and remarkable experience for their delegates, exhibitors, partners and all visitors."
The British Veterinary Association has responded to 'alarmist' headlines linking contact with cats to schizophrenia due to the risks posed by the parasite Toxoplasma gondii.
The report in today's Independent contains some important messages regarding the need for good personal hygiene and the need for pregnant women and immuno-compromised groups to be aware of the risks. However, the BVA says it is concerned that the headlines could cause significant alarm to cat owners.
Most people who become infected are asymptomatic but 10-20% can show transient symptoms which are flu-like. There is a more serious risk to pregnant women and those who are immuno-compromised, but as with all infections common sense and good personal hygiene reduces the risk significantly and the BVA says there is no reason that families with, or those intending to have, children shouldn't have pet cats.
As outlined in the article sources of infection include eating undercooked meat and vegetables that have not been washed properly and contact with cats. It is not known which the greater source of infection is but according to the BVA, anecdotal evidence suggests that meat is likely to be more important than contact with cats. The BVA says it echoes advice that meat should be prepared and cooked properly, and offers the following hygiene advice for cat owners:
BVA Past President and veterinary surgeon Harvey Locke said: "While the facts are true, the headlines in this story have been quite alarmist and we are very keen to reassure cat owners that the risks can be managed with good basic hygiene and common sense.
"The biggest threat is to pregnant women and those who are immuno-compromised, which we have known for some time. It is useful to reiterate that they should take extra care but there is no need for people to get rid of their pet cats or choose not to have cats as pets."
The Royal College of Veterinary Surgeons has launched an online quiz to test its members' knowledge of the Guide to Professional Conduct.
The Guide outlines what is acceptable professional and ethical behaviour for veterinary surgeons. It is developed and maintained by the Advisory Committee of the RCVS, which, in addition to veterinary members of RCVS Council, also includes lay members, a member of the Veterinary Nurses Council, and independent (ie non-Council) veterinary surgeons. The Guide is the benchmark against which a veterinary surgeon is judged, by both the Preliminary Investigation and Disciplinary Committees.
The quiz, which was road-tested at the London Vet Show on 6-7 November, is anonymous, but the College will be collating data on results to help focus future communications activities and see where extra guidance may be required.
On completion of the quiz, it is possible to review answers and view the relevant section of the online Guide.
The quiz is aimed at veterinary surgeons: if it's a success, a version for Registered Veterinary Nurses will follow.
To try the quiz, visit www.rcvs.org.uk/guidequiz It will initially be online for three months and reviewed thereafter.
According to the BVA, the problem is usually related to the cost of treatment, with 90% of vets saying that they or a member of their team have been challenged over their fees or charges and 98% saying that at some time they feel under pressure to waive fees or accept the promise of late payment.
Predictably, the problem is more commonly reported by those working in companion animal or mixed practice, with 89% reporting some form of intimidating experience. Younger vets and female vets were also significantly more likely to have experienced some form of intimidation.
The survey has prompted the BVA and the British Veterinary Nursing Association to issue advice concerning how to deal with intimidating clients.
BVNA President Sam Morgan said: "These statistics make for sad reading, but are certainly not surprising. Working within practice we have all either been subject to or witnessed that 'difficult' client, but we must remember any form of harassment is unacceptable. It’s important not to feel alone in these situations and to ensure there is awareness and support throughout the veterinary team."
BVA President John Fishwick, said: "Every situation is different and has to be dealt with on an individual basis, but it’s concerning to see the figures around challenging client behaviour and fees. Owning an animal is an important responsibility and will cost tens of thousands of pounds over its lifetime.
"It’s important for everyone in the vet team to take pride in the healthcare and treatment they deliver, and, equally, they must feel valued for their services. These figures emphasise the importance of managing expectations around fees by ensuring a two-way discussion about options and costs so clients can make a decision in collaboration with the veterinary team."
The BVA/BVNA advice for dealing with intimidating clients is as follows:
Photo: Dimitry A / Shutterstock
The webinar, which will be streamed live at 8pm on Wednesday 20th November and will be available to watch for six months thereafter, is being presented by James Husband, an RCVS Specialist in cattle health & production.
Topics will include oxidative stress, its impact on cattle performance and the role of trace minerals in immunity and cattle health. The webinar will also cover the current complexities of oral supplementation including absorption and mineral antagonism, along with offering information about the latest innovation to boost trace mineral availability during high demand periods in the production and breeding life cycle.
To register for the webinar, visit: https://www.thewebinarvet.com/pages/register-free-role-trace-minerals-cattle-health-performance-new-veterinary-approach-boost-trace-mineral-availability/
All vets who view the webinar, either live or as a recording on the website, will be able to download a CPD certificate.
The company says that of the 249 responses to its Puppy Tooth Census received so far (of which 40% were from vets, 21% vet nurses, 2% other veterinary professionals and 37% puppy owners), 25% were poodle crosses.
This, says the company, is in line with anecdotal reports that vets are seeing more dental conditions in poodle cross puppies.
VisioCare is now calling for more vets to take part in the survey at https://bit.ly/Visiocare_PuppyToothCensus.
With very few studies that address dental disease in puppies and a lack of current data, it is hoped that the survey will advance understanding and improve oral health and welfare.
Every veterinary respondent will be given access to a pack of educational materials to use in the consulting room, including digital animations and dental images that can be used to enhance client communication around the topic, together with explainer videos and puppy owner fact sheets and leaflets.
In addition, each month for the next three months, all responses will be entered into a prize draw for the chance to win a £50 John Lewis gift voucher.
VisioCare is also offering a free webinar: "Challenges in Puppy Dentistry and Malocclusion" presented by Ingrid Tundo, Head of the Dentistry and Oral Surgery Department at the Royal (Dick) Vet School, viewable at: https://veterinarywebinars.com/register/puppy-dentistry-malocclusion.
Finally, Nicky Diver-Clarke, Marketing Manager at VisioCare Services is also offering a free marketing CPD session for practices that want to find the best way to amplify awareness of the Puppy Tooth Census within their practice.
Anyone interested in accessing the free support can contact her at nicky@visiocareservices.co.uk.